ICU Medical (NASDAQ:ICUI) Shares Up 13.7% After Earnings Beat

ICU Medical, Inc. (NASDAQ:ICUI)’s stock price traded up 13.7% during mid-day trading on Friday after the company announced better than expected quarterly earnings. The company traded as high as $192.85 and last traded at $189.0820. 115,743 shares changed hands during mid-day trading, a decline of 60% from the average session volume of 290,658 shares. The stock had previously closed at $166.37.

The medical instruments supplier reported $2.37 EPS for the quarter, beating analysts’ consensus estimates of $1.91 by $0.46. ICU Medical had a net margin of 2.15% and a return on equity of 7.50%. The firm had revenue of $547.88 million during the quarter, compared to the consensus estimate of $533.44 million. During the same quarter last year, the firm earned $2.10 earnings per share. The firm’s revenue was up .5% compared to the same quarter last year. ICU Medical has set its FY 2026 guidance at 8.600-9.000 EPS.

More ICU Medical News

Here are the key news stories impacting ICU Medical this week:

• Positive Sentiment: Q2 earnings and revenue exceeded expectations. ICU Medical reported adjusted EPS of $2.37, well above the $1.91 analyst consensus and up from $2.10 a year earlier. Revenue reached $547.9 million, compared with estimates of $533.4 million, although sales growth was modest at 0.5% year over year. ICU Medical Announces Second Quarter 2026 Results and Updates its Fiscal Year 2026 Guidance
• Positive Sentiment: Full-year guidance is above Wall Street expectations. ICU Medical projected fiscal 2026 EPS of $8.60 to $9.00, compared with the consensus estimate of $7.83. The outlook suggests management expects earnings momentum to continue. ICU Medical Tops Q2 Earnings and Revenue Estimates
• Positive Sentiment: Analysts raised their valuation expectations. Needham increased its price target from $165 to $187 and assigned a “Buy” rating. Other analysts also lifted targets following the earnings report, reinforcing the favorable market reaction. ICU Medical Analysts Boost Their Forecasts Following Upbeat Q2 Earnings
• Neutral Sentiment: Investors should weigh valuation and profitability. Despite the earnings beat, ICU Medical’s reported net margin was just 2.15%, while its elevated valuation leaves less room for execution or guidance disappointments.

Wall Street Analysts Forecast Growth

Several research analysts have issued reports on ICUI shares. BTIG Research increased their price objective on ICU Medical from $170.00 to $200.00 and gave the stock a “buy” rating in a research report on Friday. Raymond James Financial reiterated a “strong-buy” rating and issued a $200.00 price objective on shares of ICU Medical in a research note on Friday. Wall Street Zen upgraded shares of ICU Medical from a “hold” rating to a “buy” rating in a research report on Saturday, May 9th. Weiss Ratings raised shares of ICU Medical from a “sell (d+)” rating to a “hold (c-)” rating in a report on Thursday, July 23rd. Finally, Jefferies Financial Group raised ICU Medical to a “strong-buy” rating in a research note on Thursday, May 7th. Two research analysts have rated the stock with a Strong Buy rating, four have given a Buy rating and three have assigned a Hold rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $186.40.

Insiders Place Their Bets

In other news, VP Virginia Ruth Sanzone sold 2,447 shares of the business’s stock in a transaction on Thursday, May 14th. The stock was sold at an average price of $124.08, for a total value of $303,623.76. Following the completion of the transaction, the vice president directly owned 19,460 shares of the company’s stock, valued at $2,414,596.80. The trade was a 11.17% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Director David C. Greenberg sold 2,424 shares of the company’s stock in a transaction on Tuesday, May 12th. The shares were sold at an average price of $122.91, for a total value of $297,933.84. Following the completion of the sale, the director owned 7,960 shares in the company, valued at $978,363.60. This represents a 23.34% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. 2.10% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Hilton Head Capital Partners LLC purchased a new stake in shares of ICU Medical during the fourth quarter worth about $32,000. Covestor Ltd lifted its stake in shares of ICU Medical by 22.1% during the fourth quarter. Covestor Ltd now owns 696 shares of the medical instruments supplier’s stock valued at $99,000 after buying an additional 126 shares during the period. Strs Ohio lifted its stake in shares of ICU Medical by 60.0% during the fourth quarter. Strs Ohio now owns 800 shares of the medical instruments supplier’s stock valued at $114,000 after buying an additional 300 shares during the period. Rockefeller Capital Management L.P. boosted its position in ICU Medical by 21.6% during the fourth quarter. Rockefeller Capital Management L.P. now owns 823 shares of the medical instruments supplier’s stock worth $117,000 after acquiring an additional 146 shares during the last quarter. Finally, Kemnay Advisory Services Inc. acquired a new stake in ICU Medical during the fourth quarter worth approximately $120,000. 96.10% of the stock is currently owned by hedge funds and other institutional investors.

ICU Medical Price Performance

The stock has a market capitalization of $4.65 billion, a PE ratio of 100.82, a PEG ratio of 2.32 and a beta of 0.74. The company has a current ratio of 2.34, a quick ratio of 1.17 and a debt-to-equity ratio of 0.60. The company’s 50 day simple moving average is $150.66 and its 200 day simple moving average is $140.72.

ICU Medical Company Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.